Six abstracts selected for presentation, including three oral presentationsWALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc., a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, and wholly owned ...

Innoviva, Inc. (Nasdaq: INVA) (Innoviva), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of La Jolla Pharmaceutical...

Qube Research Technologies Ltd raised its holdings in Innoviva, Inc. (NASDAQ:INVA Get Rating) by 9.3% in the first quarter, according to its most recent Form 13F filing with the Securities Exchange Commission. The fund owned 51,432 shares of the biotechnology companys ...

StockNews.com upgraded shares of Innoviva (NASDAQ:INVA Get Rating) from a hold rating to a buy rating in a research note issued to investors on Thursday morning. INVA has been the topic of a number of other reports. The Goldman Sachs Group began coverage on shares of Innoviva in a report on ...

NEW YORK, July 14, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of La Jolla Pharmaceutical Company (NASDAQ: LJPC) (La Jolla) breached their fiduciary duties or violated ...